IP Library Granted Patent US 9,956,316
Granted Patent B2
US 9,956,316 · App. 14/924,931 · Granted May 1, 2018

Method for enzymatic treatment of tissue products

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,956,316
App. No.
14/924,931
Granted
May 1, 2018
Kind
B2
Abstract

Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating a tissue matrix with a proteolytic enzyme to produce a desired pliability of the tissue matrix.

Claims (14)

1. A method for treating a tissue matrix, comprising:

selecting a dermal tissue matrix that does not contain epidermis;

treating the dermal tissue matrix with a first solution to remove substantially all cells and cellular components from the dermal tissue matrix; and

contacting the dermal tissue matrix with a second solution comprising a proteolytic enzyme under conditions sufficient to produce a desired level of pliability in the dermal tissue matrix and to increase the porosity of the dermal tissue matrix, wherein the enzyme is selected from bromelain, papain, ficin, actinidin, or combinations thereof.

2. The method of claim 1 , wherein the enzyme is bromelain.

3. The method of claim 1 , wherein the tissue matrix is contacted with the proteolytic enzyme under conditions that do not produce an undesirable change in at least one of tensile strength, tear strength, suture strength, creep resistance, burst strength, thermal transition temperature, or combinations thereof.

4. The method of claim 1 , wherein the tissue matrix is contacted with the proteolytic enzyme under conditions that do not cause a statistically significant reduction in tensile strength, tear strength, suture strength, creep resistance, thermal transition temperature, or combinations thereof.

5. The method of claim 1 , wherein the dermal tissue matrix comprises intact tissue.

6. A method for treating a tissue matrix, comprising:

selecting dermal acellular tissue matrix that does not contain epidermis; and

contacting the dermal acellular tissue matrix with a proteolytic enzyme under conditions sufficient to produce a desired level of pliability in the dermal acellular tissue matrix and to increase the porosity of the dermal acellular tissue matrix, wherein the enzyme is selected from bromelain, papain, ficin, actinidin, or combinations thereof.

7. The method of claim 6 , wherein the enzyme is bromelain.

8. The method of claim 6 , wherein the dermal acellular tissue matrix is contacted with the proteolytic enzyme under conditions that do not produce an undesirable change in at least one of tensile strength, tear strength, suture strength, creep resistance, burst strength, thermal transition temperature, or combinations thereof.

9. The method of claim 6 , wherein the dermal acellular tissue matrix is contacted with the proteolytic enzyme under conditions that do not cause a statistically significant reduction in tensile strength, tear strength, suture strength, creep resistance, thermal transition temperature, or combinations thereof.

Assignments (7)
RELEASE OF SECURITY INTEREST 040098/0268 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0554 →
RELEASE OF SECURITY INTEREST 040291/0237 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0702 →
RELEASE OF SECURITY INTEREST 037845/0497 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0603 →
LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 7, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040291/0237 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 21, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040098/0268 →
SECURITY INTEREST Recorded Feb 17, 2016
From: KINETIC CONCEPTS, INC.; KCI USA, INC.; ACELITY L.P. INC.; CHIRON HOLDINGS, INC.; CHIRON TOPCO, INC.; KCI ANIMAL HEALTH, LLC; KCI HOLDING COMPANY, INC.; KCI HOMECARE, INC.; KCI IMPORTS, INC.; KCI INTERNATIONAL, INC.; KCI LICENSING, INC.; KCI PROPERTIES LIMITED; KCI REAL HOLDINGS, L.L.C.; KCI REAL PROPERTY LIMITED; KCI USA REAL HOLDINGS, L.L.C.; LIFECELL CORPORATION; TECHNIMOTION, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 037845/0497 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2015
From: CHEN, YI
To: LIFECELL CORPORATION
Reel/Frame 036954/0425 →